Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from RELIEF THERAPEUTICS Holding ( (CH:RLF) ) is now available.
Relief Therapeutics and NeuroX have completed their business combination to form MindMaze Therapeutics, a company poised to redefine neurological care through a unique ecosystem of precision digital neurotherapeutics, pharmacological treatments, and AI-powered platforms. This merger strengthens MindMaze’s position in the industry by enhancing its growth strategy and expanding development opportunities, as it seeks to address the critical gap in motor and cognition restoration for neurological conditions. The new entity’s shares will be traded on the SIX Swiss Exchange under the ticker MMTX, marking a significant step in its mission to transform neurological care.
The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF3.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
MindMaze Therapeutics is a Swiss-based, commercial-stage company formed through the merger of Relief Therapeutics Holding SA and NeuroX Group SA. The company develops and commercializes innovative digital treatments for neurological diseases and brain disorders, utilizing an advanced brain technology platform that integrates software, sensors, and telehealth. MindMaze Therapeutics’ solutions are deployed globally across clinics and home settings, and the company continues to expand its R&D pipeline into various neurological indications.
YTD Price Performance: -31.47%
Average Trading Volume: 39,535
Technical Sentiment Signal: Sell
Current Market Cap: CHF36.36M
Find detailed analytics on RLF stock on TipRanks’ Stock Analysis page.